Design and protocol for the Dialysis Optimal Health Program (DOHP) randomised controlled trial

Simon R Knowles, Chantal F Ski, Robyn Langham, Emmet O'Flaherty, David R Thompson, Susan L Rossell, Gaye Moore, Ya-Seng Arthur Hsueh, David J Castle, Simon R Knowles, Chantal F Ski, Robyn Langham, Emmet O'Flaherty, David R Thompson, Susan L Rossell, Gaye Moore, Ya-Seng Arthur Hsueh, David J Castle

Abstract

Background: Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are serious and growing health problems with enormous impact on psychological and social functioning. Despite high rates of comorbid depression and anxiety in these patient populations, and the adverse impact these have upon treatment adherence, quality of life, social connectedness and healthcare costs there has been little attention focused on the prevention or management of these problems. Thus, our aim was to evaluate the Dialysis Optimal Health Program (DOHP) that adopts a person-centred approach and engages collaborative therapy to educate and support those diagnosed with ESKD who are commencing dialysis.

Methods: The study design is a randomised controlled trial. Ninety-six adult patients initiating haemodialysis or peritoneal dialysis will be randomly allocated to either the intervention (DOHP) or usual care group. Participants receiving the intervention will receive nine (8 + 1 booster session) sequential sessions based on a structured information/workbook, psychosocial and educational supports and skills building. The primary outcome measures are depression and anxiety (assessed by the Hospital Anxiety and Depression Scale; HADS). Secondary outcomes include health-related quality of life (assessed by the Kidney Disease Quality of Life instrument; KDQOL), self-efficacy (assessed by General Self-Efficacy Scale) and clinical indices (e.g. albumin and haemoglobin levels). Cost-effectiveness analysis and process evaluation will also be performed to assess the economic value and efficacy of the DOHP. Primary and secondary measures will be collected at baseline and at 3-, 6-, and 12-month follow-up time points.

Discussion: We believe that this innovative trial will enhance knowledge of interventions aimed at supporting patients in the process of starting dialysis, and will broaden the focus from physical symptoms to include psychosocial factors such as depression, anxiety, self-efficacy, wellbeing and community support. The outcomes associated with this study are significant in terms of enhancing an at-risk population's psychosocial health and reducing treatment-related costs and associated pressures on the healthcare system.

Trial registration: ANZCTR no. 12615000810516 . Registered on 5 August 2015.

Keywords: Chronic kidney disease; Collaborative therapy; Dialysis; End-stage kidney disease; Psychosocial health; Randomised controlled trial.

Figures

Fig. 1
Fig. 1
Flowchart of the Dialysis Optimal Health Program (DOHP) randomized controlled trial (RCT)

References

    1. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;8:1258–70. doi: 10.1038/ki.2011.368.
    1. Australian Institute of Health and Welfare . Cardiovascular disease, diabetes and chronic kidney disease— Australian facts: prevalence and incidence, cardiovascular, diabetes and chronic kidney disease series no. 2. Cat. no. CDK 2. Canberra: AIHW; 2014.
    1. ANZDATA Registry. 37th Report, Chapter 1: Incidence of End Stage Kidney Disease. Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2015. Available at:
    1. Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol. 1993;4(1):12–27.
    1. Christensen AJ, Ehlers SL. Psychological factors in end-stage renal disease: an emerging context for behavioral medicine research. J Consult Clin Psychol. 2002;70(3):712–24. doi: 10.1037/0022-006X.70.3.712.
    1. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Boyle DH, Umana WO, Kovac JA, Alleyne S, Cruz I, Veis JH. Psychologic functioning, quality of life, and behavioral compliance in patients beginning hemodialysis. J Am Soc Nephrol. 1996;7(10):2152–9.
    1. Low J, Smith G, Burns A, Jones L. The impact of end-stage kidney disease (ESKD) on close persons: a literature review. NDT Plus. 2008;2:67–79.
    1. Stasiak CES, Bazan KS, Kuss RS, Schuinski AFM, Baroni G. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol. 2014;36(3):325–31. doi: 10.5935/0101-2800.20140047.
    1. Levenson JL, Glocheski S. Psychological factors affecting end-stage renal disease. A review Psychosomatics. 1991;32(4):382–9. doi: 10.1016/S0033-3182(91)72038-0.
    1. Knowles S, Swan L, Salzberg M, Castle D, Langham R. Exploring the relationships between health status, illness perceptions, coping strategies and psychological morbidity in a chronic kidney disease cohort. Am J Med Sci. 2014;348(4):271–6. doi: 10.1097/MAJ.0000000000000242.
    1. Cukor D, Cohen SD, Peterson RA, Kimmel PL. Psychosocial aspects of chronic disease: ESRD as a paradigmatic illness. J Am Soc Nephrol. 2007;18(12):3042–55. doi: 10.1681/ASN.2007030345.
    1. Bossola M, Ciciarelli C, Di Stasio E, Conte GL, Vulpio C, Luciani G, Tazza L. Correlates of symptoms of depression and anxiety in chronic hemodialysis patients. Gen Hosp Psychiatry. 2010;32(2):125–31. doi: 10.1016/j.genhosppsych.2009.10.009.
    1. Lopes AA, Albert JM, Young EW, Satayathum S, Pisoni RL, Andreucci VE, Mapes DL, Mason NA, Fukuhara S, Wikstrom B, et al. Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int. 2004;66(5):2047–53. doi: 10.1111/j.1523-1755.2004.00977.x.
    1. Lacson E, Jr, Li NC, Guerra-Dean S, Lazarus M, Hakim R, Finkelstein FO. Depressive symptoms associate with high mortality risk and dialysis withdrawal in incident hemodialysis patients. Nephrol Dial Transplant. 2012;27(7):2921–8. doi: 10.1093/ndt/gfr778.
    1. Chilcot J, Davenport A, Wellsted D, Firth J, Farrington K. An association between depressive symptoms and survival in incident dialysis patients. Nephrol Dial Transplant. 2010;26(5):1628–34. doi: 10.1093/ndt/gfq611.
    1. Bonner A, Havas K, Douglas C, Thepha T, Bennett P, Clark R. Self-management programmes in stages 1–4 chronic kidney disease: a literature review. J Ren Care. 2014;40(3):194–204. doi: 10.1111/jorc.12058.
    1. Sareen J, Jacobi F, Fox B, Belik S, Clara I, Stein M. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med. 2006;166:2109–16. doi: 10.1001/archinte.166.19.2109.
    1. McKercher C, Sanderson K, Jose MD. Psychosocial factors in people with chronic kidney disease prior to renal replacement therapy. Nephrology. 2013;18:585–91. doi: 10.1111/nep.12138.
    1. Rabindranath KS, Daly C, Butler JA, Roderick PJ, Wallace S, Macleod AM. Psychosocial interventions for depression in dialysis patients. Cochrane Database Syst Rev. 2005;3:CD004542.
    1. Kimmel PL, Peterson RA. Depression in patients with end-stage renal disease treated with dialysis: has the time to treat arrived? Clin J Am Soc Nephrol. 2006;1(3):349–52. doi: 10.2215/CJN.00890306.
    1. Castle D, Gilbert M. Collaborative therapy: framework for mental health. Br J Psychiatry. 2006;189:467. doi: 10.1192/bjp.189.5.467.
    1. Castle D, White C, Chamberlain J, Berk M, Berk L, Lauder S, Murray G, Schweitzer I, Piterman L, Gilbert M. Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. Br J Psychiatry. 2010;196:383–8. doi: 10.1192/bjp.bp.108.058263.
    1. Gilbert M, Chamberlain J, White C, Mayers P, Pawsey B, Liew D, Musgrave M, Crawford K, Castle D. Controlled clinical trial of a self-management program for people with mental illness in an adult mental health service–the optimal health program (OHP) Aust Health Rev. 2012;36:1–7. doi: 10.1071/AH11008.
    1. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J, Weiller E, Bonara LI, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC. Reliability and validity of the M.I.N.I. International Neuropsychiatric Interview (M.I.N.I.): according to the SCID-P. Eur Psychiatry. 1997;12:232–41. doi: 10.1016/S0924-9338(97)83297-X.
    1. Richardson J, Peacock S, Hawthorne G, Iezzi A, Elsworth G, Atherton DN. Construction of the descriptive system for the assessment of quality of life: AQoL-6D utility instrument. Health Qual Life Outcomes. 2012;10(38):1–9.
    1. Konerding U, Elkhuizen S, Faubel R, Forte P, Malmström T, Pavi E, Janssen M. The validity of the EQ-5D-3 L items: an investigation with type 2 diabetes patients from six European countries. Health Qual Life Outcomes. 2014;12:181. doi: 10.1186/s12955-014-0181-5.
    1. Diggle P, Heagerty P, Liang K, Zeger S. Analysis of longitudinal data. 2. Oxford: Oxford University Press; 2002.
    1. Schulz FK, Altman GD, Mother D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):1–8. doi: 10.7326/0003-4819-152-11-201006010-00232.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Hays RD, et al. Kidney Disease Quality of Life Short Form (KDQOL-SF™), version 1.3: a manual for use and scoring. Santa Monica: RAND; 1997. p. 7994.
    1. Bosscher RJ, Smit JH. Confirmatory factor analysis of the General Self-Efficacy Scale. Behav Res Ther. 1998;36(3):339–43. doi: 10.1016/S0005-7967(98)00025-4.
    1. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006;60:631–7. doi: 10.1016/j.jpsychores.2005.10.020.
    1. Carver C, Scheier M, Weintraub J. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989;56:267–83. doi: 10.1037/0022-3514.56.2.267.
    1. Carver C. You want to measure coping but your protocol’s too long: consider the Brief COPE. Int J Behav Med. 1997;4:92–100. doi: 10.1207/s15327558ijbm0401_6.
    1. Gosling S, Rentfrow P, Swann W., Jr A very brief measure of the big five personality domains. J Res Pers. 2003;37:504–28. doi: 10.1016/S0092-6566(03)00046-1.
    1. Mundt J, Marks I, Shear K, Greist J. The work and social adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461–4. doi: 10.1192/bjp.180.5.461.
    1. Devilly G, Borkovec T. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31:73–86. doi: 10.1016/S0005-7916(00)00012-4.
    1. Newton J, Sturmey P. Development of a short form of the Treatment Evaluation Inventory for acceptability of psychological interventions. Psychol Rep. 2004;94:47–81. doi: 10.2466/pr0.94.2.475-481.
    1. Hsueh A. Health Care Utilisation Questionnaire (HCUQ) based on Thorn JC, Coast J, Cohen D, Hollingworth W, Knapp M, Noble SM, Ridyard C, Wordsworth S, Hughes D. Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation. Appl Health Econ Health Policy. 2013;11:155–61.
    1. Nich C, Carroll K. Now you see it, now you don’t: a comparison of traditional versus random-effects regression models in the analysis of longitudinal follow-up data from a clinical trial. J Consult Clin Psychol. 1997;65(2):252–61. doi: 10.1037/0022-006X.65.2.252.
    1. Schafer J, Graham J. Missing data: our view of the state of the art. Psychol Methods. 2002;7(2):147–77. doi: 10.1037/1082-989X.7.2.147.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir